Bruker Co. (NASDAQ:BRKR) has received a consensus recommendation of “Hold” from the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $31.83.

Several analysts have issued reports on BRKR shares. BTIG Research started coverage on Bruker in a research note on Friday, January 5th. They issued a “buy” rating and a $42.00 target price for the company. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Thursday, January 4th. BidaskClub lowered Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 target price on shares of Bruker in a research note on Thursday, December 14th. Finally, Cowen reaffirmed a “hold” rating and issued a $29.00 target price on shares of Bruker in a research note on Friday, November 3rd.

Hedge funds have recently made changes to their positions in the business. Koch Industries Inc. lifted its position in Bruker by 2,573.5% in the second quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after purchasing an additional 322,252 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in Bruker by 186.3% in the second quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 10,723 shares during the last quarter. Teachers Advisors LLC lifted its position in Bruker by 65.8% in the second quarter. Teachers Advisors LLC now owns 245,720 shares of the medical research company’s stock valued at $7,087,000 after purchasing an additional 97,491 shares during the last quarter. Verition Fund Management LLC lifted its position in Bruker by 95.6% in the second quarter. Verition Fund Management LLC now owns 26,891 shares of the medical research company’s stock valued at $776,000 after purchasing an additional 13,140 shares during the last quarter. Finally, Stifel Financial Corp bought a new stake in Bruker in the second quarter valued at approximately $575,000. Hedge funds and other institutional investors own 65.60% of the company’s stock.

Shares of Bruker (NASDAQ BRKR) traded up $0.94 on Friday, reaching $35.20. The company’s stock had a trading volume of 779,111 shares, compared to its average volume of 482,916. The stock has a market capitalization of $5,480.00, a price-to-earnings ratio of 37.45, a P/E/G ratio of 2.57 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. Bruker has a 1-year low of $21.83 and a 1-year high of $36.53.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The business had revenue of $435.60 million during the quarter, compared to analyst estimates of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. Bruker’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 earnings per share. equities research analysts anticipate that Bruker will post 1.19 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were given a $0.04 dividend. The ex-dividend date of this dividend was Friday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.45%. Bruker’s payout ratio is currently 17.02%.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/19/bruker-co-brkr-given-average-rating-of-hold-by-analysts.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.